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Abstract: Increased osteoclast (OC) differentiation and activity is the critical event that results in
bone loss and joint destruction in common pathological bone conditions, such as osteoporosis
and rheumatoid arthritis (RA). RANKL and its decoy receptor, osteoprotegerin (OPG), control OC
differentiation and activity. However, there is a specific concern of a rebound effect of denosumab
discontinuation in treating osteoporosis. TNFα can induce OC differentiation that is independent
of the RANKL/RANK system. In this review, we discuss the factors that negatively and positively
regulate TNFα induction of OC formation, and the mechanisms involved to inform the design of
new anti-resorptive agents for the treatment of bone conditions with enhanced OC formation. Similar
to, and being independent of, RANKL, TNFα recruits TNF receptor-associated factors (TRAFs) to
sequentially activate transcriptional factors NF-κB p50 and p52, followed by c-Fos, and then NFATc1
to induce OC differentiation. However, induction of OC formation by TNFα alone is very limited,
since it also induces many inhibitory proteins, such as TRAF3, p100, IRF8, and RBP-j. TNFα induction
of OC differentiation is, however, versatile, and Interleukin-1 or TGFβ1 can enhance TNFα-induced
OC formation through a mechanism which is independent of RANKL, TRAF6, and/or NF-κB.
However, TNFα polarized macrophages also produce anabolic factors, including insulin such as
6 peptide and Jagged1, to slow down bone loss in the pathological conditions. Thus, the development
of novel approaches targeting TNFα signaling should focus on its downstream molecules that do not
affect its anabolic effect.
Keywords: osteoclast; tumor necrosis factor alpha (TNFα); nuclear factor-kappa B (NF-κB); receptor
activator of NF-κB ligand (RANKL); osteoprotegerin (OPG); TNF receptor-associated factor 3 (TRAF3);
recombination signal–binding protein jκ (RBPjκ); interferon-regulatory factor 8 (IRF8); interleukin-1β
(IL-1β); transforming growth factor-β1 (TGF-β1)
1. Introduction
Bone is a dynamic structure that undergoes constant remodeling throughout life, in
which mature bone tissue is removed by osteoclasts (OCs), a process called bone resorption,
and new bone tissue is formed by osteoblasts (OBs), a process called bone formation.
Imbalance of bone remodeling (increased OC bone resorption and/or decreased OB bone
formation) results in bone loss, contributing to common diseases affecting adult bone,
including osteoporosis [1–3], rheumatoid arthritis (RA), [4,5], bone metastatic cancer [6,7],
aseptic loosening of arthroplasty [8], and periodontitis [9]. In postmenopausal osteoporosis,
bone resorption is increased, associated with a coupled increase in bone formation [1–3],
but bone formation relative to bone resorption is reduced [10], resulting in the accelerated
bone turnover, and, finally, bone loss. Similarly, the ectopic differentiation and activation of
OCs are essential for joint destruction seen in the inflamed joints of RA [4,5].
Several anti-resorptive and anabolic agents are available to treat osteoporosis. The
widely prescribed anti-resorptive drugs, bisphosphonates [11], effectively increase bone
mass, and reduce the rate of osteoporotic fracture by 50% [12]. As a result of the wider
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use of these therapies, the incidence of osteoporotic fracture has declined in developed
countries [13]. For example, between 1980 and 2006, the overall incidence of hip fractures
declined by 1.42% per year in women, and 0.44% per year in men in the Rochester area,
US [14]. However, the rate of osteoporotic fracture is no longer declining, and for some
fracture types, the rates have been rising in recent years [15].
Of concern is that bisphosphonates can result in atypical femoral fractures [16,17],
hypocalcemia [18], and osteonecrosis of jaw bone [19,20] in a small number of patients.
It is generally accepted that the incidence of jaw bone necrosis is rare in patients who
take oral bisphosphonate, ranging from 0.01% to 0.99%. [21]. However, some reports
have indicated that jaw bone necrosis is more frequent, approximately 4%, in osteoporotic
patients taking long-term bisphosphonate orally [19]. The prevalence of bone necrosis
is even higher in patients who are taking high-dose intravenous bisphosphonates [22].
Another anti-resorptive agent, denosumab (RANKL inhibitor), can also result in bone
necrosis [23]. One special concern for denosumab is that its discontinuation is associated
with a subsequent profound increase of bone turnover above pre-treatment values due to
a substantial increase in OC number and activity, resulting in a risk of multiple vertebral
fractures [24,25]. In addition, both bisphosphonates and denosumab do not effectively
prevent focal joint destruction in human RA [26,27].
The anabolic agents include teriparatide (N-terminus 34 amino acid of parathyroid
hormone) and newly FDA-approved abaloparatide (a parathyroid hormone-related protein
analog) [28]. However, the effect of anabolic agents to increase bone mass is transient, and
discontinuing these agents abruptly decreases bone mineral density (BMD) [29] due to
increased bone resorption [30]. Therefore, the use of these anabolic treatments must be
followed by anti-resorptive agents [28]. It has also shown that combined therapy with
teriparatide and a bisphosphonate does not appear to offer advantages over the use of
the single agent alone [31,32]. Similarly, switching from alendronate to teriparatide does
not improve patients’ hip BMD, although the addition of an anabolic agent to ongoing
alendronate does [33]. However, when patients established on potent bisphosphonates
and denosumab are switched to teriparatide, the hip BMD declines below baseline for at
least 12 and 24 months, respectively, after the switch to this anabolic agent [33]. Thus, for
the osteoporosis treatment sequence, the anabolic therapy should be given first, followed
by potent antiresorptive therapy. In addition, there are concerns that long-term use of
anabolic agents may induce osteosarcoma, and their use is therefore generally limited to
1–2 years [34–37].
The newly approved romosozumab (a sclerostin monoclonal Ab) has a dual effect to in-
crease bone formation early (and transiently), while inhibiting bone resorption persistently
to treat osteoporosis [38]. However, it can increase the risk of severe side-effects, including
myocardial infarction, stroke, and cardiovascular death [36]. Thus, romosozumab is only
recommended for treatment of severe osteoporosis for up to 1 year [39].
In summary, the efficacy of current anti-resorptive and anabolic agents in treating
osteoporosis and other bone diseases is limited, and their side effects have resulted in poor
patient compliance, with many patients going untreated [40,41]. Thus, there is an unmet
need to develop a new class of anti-resorptive drug for the treatment of diseases with
enhanced bone resorption, including osteoporosis and RA. Considering the central role of
OCs in bone diseases with bone loss, and the severe rebound effect of denosumab discon-
tinuation, we review the signaling pathways for RANKL-independent OC differentiation
in order to inspire the development of novel RANKL-independent anti-resorptive agents
for the treatment of these bone diseases with bone loss.
2. Origin and Biological Characteristics of OC
An OC is a multinucleated cell with three or more nuclei, and is normally located
on the trabecular surface. The cytoplasm of an OC has a high concentration of vesicles
and vacuoles, including lysosomes filled with acid phosphatase (permitting the cell to be
stained for the high activity of tartrate resistant acid phosphatase (TRAP)) and cathepsin K.
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An activated OC is characterized by cytoskeletal reorganization, the formation of sealing
zones, and a specialized cell membrane, called a ruffled border, which opposes the surface
of the bone tissue, allowing the secretion of acids and lysosomal enzymes onto the surface
of bone to be resorbed [42,43]. Being deficient in sealing zone and ruffled border, as a
result of defect of src kinase [44] or αv/β3 integrin [45], for example, incur OCs losing
their resorptive function in mice. However, mutation of src kinase has not been identified
in human patients with osteopetrosis [46,47]. Similarly, there is no report showing that
an αv/β3 integrin genetic mutation causes abnormal OC function and osteopetrosis in
humans, although defects in αIIb/β3 integrin causes Glanzmann thrombasthenia with
bleeding in humans [48].
In postmenopausal osteoporosis, OC formation is increased with increased circulating
bone resorptive markers [1–3], and OC resorptive function is also enhanced [49]. Normally,
an OC does not present in the joint space, articular cartilage, or synovial tissue; however,
in RA, OCs are ectopically differentiated and activated in the inflamed synovium and the
adjacent articular cartilage where they actively erode cartilage and subchondral bone. OC
formation is increased, and its function on the trabecular surface is enhanced, resulting in
systemic osteoporosis in RA, particularly in patients treated with corticosteroids [50,51].
It has long been known that OCs originate from mononuclear phagocytes [52–55],
which comprise monocytes/macrophages and dendritic cells (DC) originated from the
common macrophage/DC progenitors (MDPs) [56]. Macrophage-colony stimulating factor
(M-CSF) and its receptor, c-Fms, are required for macrophage generation [57], and for OC
differentiation, since a deficiency of M-CSF results in osteopetrosis in mice, due to the lack
of OC [58–60]. The mononuclear cells from any tissue, including bone marrow, spleen,
thymus, or peripheral blood, can differentiate into TRAP+ OCs in vitro [61], and thus,
monocytes/macrophages that have potential to form OCs are called OC precursors (OCPs).
DCs can transdifferentiate toward functional OCs upon inflammatory conditions [62]. Thus,
depletion of plasmacytoid dendritic cells inhibits osteolysis caused by breast cancer bone
metastasis [63]. However, as a DC stimulating factor, granulocyte macrophage-colony
stimulating factor (GM-CSF), strongly inhibits OC formation [64], although it stimulates the
fusion of mononuclear OC precursors into bone-resorbing OCs by activating the Ras/ERK
pathway [65].
OC differentiation from monocytes/macrophages requires M-CSF, but alone it is
unable to complete the OC differentiation process [66]. In the late 1990s, two independent
groups discovered that the receptor activator of nuclear factor-kappa B (NF-κB) ligand
(RANKL), also named osteoprotegerin (OPG) ligand or osteoclast differentiation factor
(ODF), is the additional factor that drives the terminal OC differentiation [67,68].
3. RANKL/OPG Signaling in Control of OC Differentiation
RANKL is a member of TNF superfamily of cytokine. Its receptor, RANK, with
partial homology to a portion of the extracellular domain of human CD40, a member of
TNF receptor superfamily, was discovered earlier to be involved in T-cell activation and
dendritic-cell function [69]. Genetic deletion or mutation of RANKL or RANK results in
severe osteopetrosis due to a complete OC defect [67,70]. When co-stimulated with M-CSF,
the binding of RANKL with RANK in OCPs results in terminal OC differentiation, fusion,
and activation. However, like other members of the TNF receptor super-family, RANK
lacks intrinsic kinase activity to mediate downstream signaling [71]. The binding of RANKL
to RANK recruits a variety of molecules, including the multifunctional adaptor proteins;
TNF receptor-associated factors (TRAFs) 1, 2, 3, 5, and 6; and kinases, such as TGFβ-
activated kinase-1 (TAK1), [71], to sequentially activate NF-κB p50 and p52, c-Fos, and
NFATc1, the three sets of transcriptional factors that are required for OC differentiation [72].
NFATc1 is the master transcription factor regulating OC differentiation [73,74], and thus,
over-expression of NFATc1 results in the terminal differentiation and fusion of OCPs
without adding RANKL [73,74], and can rescue the defect of RANKL- and TNF-induced
OC formation caused by the deletion of NF-κB p50/p52 or c-Fos [72,75].
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OPG is a soluble decoy receptor of RANKL, and binds RANKL, blocking RANKL-
RANK interaction, inhibiting OC formation and bone resorption [76]. Thus, genetic deletion
of OPG leads to osteoporosis in mice [77,78], and homozygous deletion of 100 kilobases of
OPG gene in human results in juvenile Paget’s disease, characterized by osteopenia and
fractures [79].
RANKL/OPG ratio is thought to be a major determinant of OC differentiating status
and bone mass [80]. It is thought that RANKL increases while OPG is decreased, leading to
an increase in the ratio of RANKL to OPG, enhancing osteoclastogenesis in common bone
diseases, such as osteoporosis and RA [80]. However, some published data indicates that
serum levels of RANKL are reduced [81,82] while OPG is increased [55,83,84] with aging
and in postmenopausal osteoporotic women. In addition, TNF-Tg mice generated to have a
deficiency of RANKL still developed synovial inflammation, although joint destruction was
blocked due to OC defect [4,5]. Clinical trials indicate that RANKL inhibitor, denosumab,
did not alter RA disease activity [27,85], and did not suppress joint space narrowing,
although it caused sustained suppression of bone turnover in RA patients [27]. These
findings suggest that factors other than RANKL/OPG may play a role in enhancing OC
differentiation in pathological conditions including osteoporosis and RA. It is important to
elucidate the identity of the factors mediating enhanced OC formation, and to investigate
their activation and mode of action resulting in the bone loss and joint destruction observed.
4. TNFα Induction of OC Formation Independent of RANKL Signaling
Kobayashi et al. [86] found that mouse bone marrow macrophages (M-BMMϕ) formed
TRAP+ OCs in response to TNFα in the presence of M-CSF, which was inhibited by anti-
bodies against either TNF receptor 1 (TNFR1) or TNFR2, but not by OPG or anti–RANK
antibody. Similarly, TNF-induced OC formation from M-BMMϕ was impaired in the
absence of either TNFR1 or TNFR2 [86]. In addition, a combined treatment of TNFα and
TGF-β1 also induces OC formation from RANk−/− OCPs in vitro [87]. These findings
suggest that TNF-induced OC differentiation is independent of RANKL/OPG system.
Like RANKL, TNFα did not induce OC formation from primary spleen cells or M-
CSF-induced macrophages (Sp-Mϕ) of NF-κB p50/p52 double knockout (dKO) mice,
suggesting that TNFα induction of OC differentiation requires the expression of NF-κB
p50 and p52 [72]. Interestingly, and also similar to RANKL, TNF-induced c-Fos mRNA
expression and activation was impaired in the dKO Sp-Mϕ, and c-Fos over-expression
rescued TNF-induced OC formation from dKO Sp-Mϕ [72], suggesting that c-Fos is a
downstream signaling of NF-κB for TNF- and RANKL- induced OC formation. Interest-
ingly, over-expression of NFATc1, the down-stream transcriptional factor of c-Fos during
OC differentiation [75], results in OC formation from both WT and NF-κB p50/p52 double
knockout OCPs without the addition of RANKL or TNFα, and significantly enhances
both RANKL and TNFα induction of OC formation from both WT and NF-κB p50/p52
double knockout OCPs [72]. These findings suggest that, like RANKL, TNFα sequentially
activates transcriptional factors NF-κB, followed by c-Fos, and finally NFATc1, to induce
OC formation. The potential of TNFα to induce OC formation is, however, weak [72], and
TNFα pre-activated OCPs expressing c-Fos produce IL-1β in an autocrine mechanism by
interacting with bone matrix protein, which further induces TNFα pre-activated OCPs to
form mature OCs to resorb bone [88]. The key factors that mediate TNFα-induced OC
differentiation are highlighted in Figure 1.
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Figure 1. Key factors that mediate TNF-induced OC differentiation. (1) Similar to, and independent 
of, RANKL, TNFα sequentially activates NF-κB p50 and p52, then c-Fos, followed by NFATc1 to 
induce OC differentiation; (2) TNFα pre-activated OCPs expressing c-Fos attach to bone, and (3) are 
stimulated by bone matrix proteins, such as dentin sialoprotein (DSP), to produce IL-1β, which me-
diates the terminal differentiation of pre-activated OCPs into mature OCs to degrade bone. 
It was however puzzling that TNFα did not induce OC formation when it was ad-
ministered in vivo to Rank knockout mice [89]. Lam et al. found that TNFα alone failed to 
induce OC formation from a pure M-BMMφ, whereas it dramatically stimulated their dif-
ferentiation in the presence of permissive levels of RANKL [90], suggesting a synergistic 
effect of TNFα and RANKL on OC differentiation, and an important role of TNFα in OC 
formation in vivo on the bone surface where osteoblasts and osteocytes express permis-
sive levels of RANKL [90]. Thus, it was proposed that TNFα induction of OC differentia-
tion required the priming of OCPs by the permissive levels of RANKL in vivo, which 
explained why the administration of TNFα could not induce OC formation in vivo of 
RANK knockout mice. There is also, however, the possibility that TNFα induces unknown 
inhibitory factors to limit OC differentiation. Many negative and positive factors that reg-
ulate TNF-induced OC differentiation have in fact been identified, which are listed in Ta-
ble 1 along with their reported functions. 
Table 1. Factors that regulate TNF-induced OC differentiation. 
Class Factors Functions 
Negative regulators 
TRAF3 
Inhibits OC formation directly by preventing p100 pro-
cessing [91–93], and indirectly by limiting RANKL produc-
tion by MPCs [94].  
NF-κB2 p100 Inhibits OC formation [91]. * 
RBP-j Suppresses NFATc1 to inhibit OC formation [95]. 
IRF8 Inhibits OC formation [96,97]. 
Positive regulators 
IL-1β  Promotes TNF-pre-activated OCPs expressing c-Fos to form 
OCs independent of NF-κB p50 and p52 [88]. 
TGFβ1 Enhances TNF-induced OC formation independent of 
RANKL, RANK, and TRAF6 [87,93]. 
RANKL Degrades TRAF3 to enhance TNF-induced OC formation 
[93]. 
Figure 1. Key factors that mediate TNF-induced OC differentiation. (1) Similar to, and independent
of, RANKL, TNFα sequentially activates NF-κB p50 and p52, then c-Fos, followed by NFATc1 to
induce OC differentiation; (2) T Fα pre-activated OCPs expressing c-Fos attach to bone, and (3) are
stimulated by bone matrix proteins, such as dentin sialoprotein (DSP), to produce IL-1β, which
mediates he terminal differen iation of pre-activated OCPs into mature one.
It was however puzzling that TNFα did not induce OC formation when it was ad-
ministered in vivo to Rank knockout mice [89]. Lam et al. found that TNFα alone failed
to induce OC formation from a pure M-BMMϕ, whereas it dramatically stimulated their
differentiation in the presence of permissive levels of RANKL [90], suggesting a synergistic
effect of TNFα and RANKL on OC differentiation, and an important role of TNFα in OC
formation in vivo on the bone surface where osteoblasts and osteocytes express permissive
levels of RANKL [90]. Thus, it was proposed that TNFα induction of OC differentiation
required the priming of OCPs by the permissive levels of RANKL in vivo, which explained
why the administration of TNFα could not induce OC formation in vivo of RANK knockout
mice. There is also, however, the possibility that TNFα induces unknown inhibitory factors
to limit OC differentiation. Many negative and positive factors t regulate TNF-induced
OC differentiation have in fact been identified, which are listed i Table 1 along with thei
reported fu ctions.
Table 1. Factors that regulate TNF-induced OC differentiation.
Class Factors Functions
Negative regulators
TRAF3 Inhibits OC formation directly by preventing p100 processing [91–93], andindirectly by limiting RANKL production by MPCs [94].
NF-κB2 p100 Inhibits OC formation [91] *.
RBP-j Suppresses NFATc1 to inhibit OC formation [95].
IRF8 Inhibits OC formation [96,97].
Positive regulators
IL-1β Promotes TNF-pre-activated OCPs expressing c-Fos to form OCs independentof NF-κB p50 and p52 [88].
TGFβ1 Enhances TNF-induced OC formation independent of RANKL, RANK, andTRAF6 [87,93].
RANKL Degrades TRAF3 to enhance TNF-induced OC formation [93].
NF-κB RelB Mediates TNF-polarized i flammatory Mϕ to enhance OC formation, butinhibits NFATc1 expression to limit terminal OC differentiation [98].
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Table 1. Cont.
Class Factors Functions
Untested factors known to
regulate RANKL-induced
OC formation **
Notch ligands Inhibits OC formation directly by suppressing cFms expression by OCPs [99],and indirectly by reducing RANKL production [100].
Notch intracellular
domain
Limits OPG production by MPCs [101].
IFN-γ Polarizes M-CSF-induced resident to inflammatory Mϕ [102], and stronglyinhibits OC formation [103].
GM-CSF Polarizes inflammatory Mϕ [102], induces DCs, and inhibits OCformation [64].
LPS Polarizes inflammatory Mϕ [102], and inhibits OC formation [104], whilepromoting OC formation from pre-activated OCPs [105].
IL-12 Inflammatory Mϕ cytokine, inhibiting OC formation [106,107].
IL-18 Inflammatory Mϕ cytokine, inhibiting OC formation [106,107].
STAT1 Transcription factor that polarizes inflammatory Mϕ to mediate IFN-γ, IFN-β,and LPS inhibition of RANKL-induced OC formation [103,108].
IL-4 Cytokine that polarizes resident Mϕ through STAT6 to inhibit OC formationand activity [109,110].
IL-13 Works similarly with IL-4 to inhibit OC formation [109,110].
IL-10 Resident Mϕ cytokine that inhibits OC formation by suppressingRANKL-induced NFATc1, c-Fos, and c-Jun expression [111,112].
* Intact NF-κB1 and NF-κB2 is required for both RANKL- and TNF-induced OC differentiation [72]. ** Whether
these factors regulate TNF-induced OC differentiation have not been tested.
5. Intracellular Factors That Limit TNFα Induction of OC Differentiation
5.1. Non-Canonical NF-κB2 Signaling Proteins
5.1.1. NF-κB2 p100
NF-κB proteins include NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and its
precursor p100), RelA (p65), RelB, and c-Rel. NF-κB protein homo- and heterodimers
activate the transcription of target genes, typically through canonical (RelA:p50) and
non-canonical (RelB:p52) pathways [113,114]. In the unstimulated cells, NF-κB dimers
are retained in the cytoplasm by the inhibitory NF-κB proteins, called IκB, through their
multiple ankyrin repeats [115]. Upon stimulation, IκBα is phosphorylated and degraded
by a trimeric IκB kinase (IKK) complex, consisting of two catalytic subunits (IKKα and
IKKβ) and a regulatory subunit, IKKγ [116,117], followed by the release of p50 from p105.
As a result, RelA:p50 dimers are translocated to the nucleus to activate the target genes,
which is called the canonical NF-κB signaling pathway [116], and occurs very rapidly,
observed within minutes of stimulation. The key to non-canonical NF-κB signaling is the
processing of p100 to p52 through NF-κB-inducing kinase (NIK). In unstimulated cells,
NIK undergoes constitutive ubiquitin degradation by the TRAF3–TRAF2 complex. Upon
stimulation, TRAF3 is degraded through ubiquitination, resulting in the accumulation of
newly synthesized NIK [118], which phosphorylates IKKα. As a result, p100 is processed
to p52 to release RelB:p52 heterodimers [119,120], which translocate into the nucleus,
activating target genes. The key molecules that regulate NF-κB activation are highlighted
in Figure 2.
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single knockout of either NF-κB1 p50 or NF-κB2 p52 had normal OC numbers and func-
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κB2 p100/p52 in OC differentiation in physiological and pathological conditions. 
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mice was similar to that induced by RANKL from those of WT or NF-κB2−/− mice in vitro 
[91]. Consistent with this, TNFα also induced a greater c-Fos and NFATc1 expression in 
NFKB2−/− cells than WT cells, their expression level in NFKB2−/− cells being similar to that 
induced by RANKL when mature OCs were forming [91]. Administration of TNFα in-
duced significantly more OCs and a higher level of serum TRAP5b, a specific marker of 
bone resorption released by OCs, in NF-κB2−/− mice than in WT mice [91], suggesting that 
NF-κB2 inhibits TNF-induced OC differentiation. NF-κB2 includes the precursor protein, 
p100, and the active form protein, p52. To determine if the inhibitory effect of NF-κB2 on 
TNF-induced OC differentiation is attributed to p100 or p52 over-expression, M-CSF-in-
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Figure 2. NF-κB signaling pathway. (1) Canonical NF-κB activation. Cytokines, such as RANKL and
T Fα, induce canonical signaling by recruiting TRAF6 and TRAF2/5, respectively, to their receptors
t ti t a co plex consisting of IK -α, IK -β, and IK -γ (NEMO), which induces phosphorylation
and degradation of IκB-α, and the release of p65/p50 heterodim s, which translocate to the nucleus
to activate the t rget gene expression. (2) Non-can ic l NF-κB activation. In unstimulated cells,
the TRAF3–TRA2 complex results in constitutive NIK degradation, and thus, p100 binds RelB to
be remained trapped in cytoplasm. Cytokines, such as CD40L and RANKL, recruit cIAP to the
TRAF2–TRA3 complex, resulting in TRAF3 ubiquitin degradation, and allowing newly synthesized
NIK accumulation. NIK then phosphorylates IKK-α, which leads to proteasomal processing of p100
to p52, releasing RelB:p52 heterodimers for translocation to the nucleus. TNFα does not degrade
TRAF3, and thus, NIK is degraded, leading to the accumulation of p100 in the cytoplasm of osteoclast
precursors to limit their differentiation.
The role of NF-κB in OC differentiation was discovered in the late 1990s when NF-
κB1−/− mice were crossed with NF-κB2−/− mice to generate NF-κB1/2 double knockout
(dKO) mice that developed severe osteopetrosis due to an OC defect [121,122]. However,
single knockout of either NF-κB1 p50 or NF-κB2 p52 had normal OC numbers and function
in vivo in mice [123]. This raises the question as to the role of NF-κB1 p105/p50, NF-κB2
p100/p52 in OC differentiation in physiological and pathological conditions.
Unexpectedly, the number of OCs induced by TNFα from spleen cells of NF-κB2−/−
mice was similar to that induced by RANKL from those of WT or NF-κB2−/− mice
in vitro [91]. Consistent with this, TNFα also induced a greater c-Fos and NFATc1 ex-
pression in NFKB2−/− cells than WT cells, their expression level in NFKB2−/− cells being
similar to that induced by RANKL when mature OCs were forming [91]. Administration
of TNFα induced significantly more OCs and a higher level of serum TRAP5b, a specific
marker of bone resorption released by OCs, in NF-κB2−/− mice than in WT mice [91],
suggesting that NF-κB2 inhibits TNF-induced OC differentiation. NF-κB2 includes the
precursor protein, p100, and the active form protein, p52. To determine if the inhibitory
effect of NF-κB2 on TNF-induced OC differentiation is attributed to p100 or p52 over-
expression, M-CSF-induced macrophages from WT and NF-κB2−/− mouse spleen cells
were over-expressed with p100 or p52 by the retroviral vector, followed by treatment with
TNFα or RANKL in the presence of M-CSF. The results indicated that over-expression
of p100, but not p52, significantly inhibited TNFα- and RANKL-induced OC formation,
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confirming that p100 is responsible for TNFα inhibition of OC differentiation [91]. This is
consistent with earlier findings that TNFα-induced p100 was not processed to p52, and
thus, was accumulated in the cells [124].
Similar to its effects in WT cells, TNFα also induced accumulation of p100 in RANK−/−
and RANKL−/− OCPs. Interestingly, spleen cells from RANK−/−/NFKB2−/− and RANKL−/−/
NFKB2−/− mice formed significantly more OCs than cells from RANK−/−/NFKB2+/−
and RANKL−/−/NFKB2+/− mice in response to TNFα [91]. Although the osteopetrotic
phenotype of RANK−/− or RANKL−/− mice was not changed by NF-κB2 gene deletion,
local administration of TNFα induced many OCs and resorption lacunae in the calvarial
bones of RANK−/−/NFKB2−/− and RANKL−/−/NFKB2−/− mice [91]. In contrast, only
occasional OCs were observed in the sections of TNF-injected RANKL−/− or RANK−/−
mice [91], as reported previously [89]. These findings provided the first in vivo evidence
showing that TNFα induces functional OC differentiation, which is independent of RANKL
signaling, whereas its ability to induce OC formation is limited by its induction of p100.
A question that must be answered is whether there is a pathological significance for
TNF-induced OCs in the absence of p100, since p100 deficiency does not change the os-
teopetrotic phenotype of RANKL−/− mice [91]. TNF-Tg mice were crossed with NFkB2−/−
mice to generate TNF-Tg/NFKB2−/− mice. Interestingly, they developed joint deformity
earlier, with more severe joint inflammation and erosion than their TNF-Tg littermates [91].
TNF-Tg/NFKB2−/− mice also had reduced trabecular bone volume and cortical thick-
ness, associated with increased OC numbers and surfaces on the trabeculae compared
with TNF-Tg/NFKB2+/− mice, as evaluated by histomorphometry and 3-dimensional µCT
imaging [91]. However, serum TNF concentration in TNF-Tg/NFKB2−/− mice did not
increase compared with TNF-Tg/NFKB2+/− littermate mice. These findings suggest that
NFKB2 deficiency accelerates joint inflammation and bone erosion in a TNFα-stimulated
mouse model of RA. However, it is still unknown if NFKB2 deficiency occurs in humans to
involve in the pathological process in RA patients.
5.1.2. TRAF3
The hallmark of non-canonical NF-κB activation is p100 processing into p52 by NIK,
and TRAF3 inducing NIK constitutive ubiquitin degradation to negatively regulate non-
canonical NF-κB signaling [125,126]. Interestingly, protein levels of TRAF3 parallel the
change of p100 during RANKL- and TNFα-induced OC formation, with TNFα inducing a
high protein level of TRAF3, whereas RANKL degrades it [91]. Importantly, treatment of
OCPs with TRAF3 siRNA prevents TNFα- induced NF-κB2 p100 accumulation and inhibi-
tion of osteoclastogenesis [91], whereas over-expression of TRAF3 inhibits RANKL-induced
OC formation directly [92]. These findings confirmed that TRAF3 negatively regulates
OC differentiation by preventing p100 processing. Consistent with this specific deletion
of TRAF3 in myeloid progenitor cells in mice, results in mild osteoporosis associated with
increased OC formation [92], further confirming that TRAF3 maintains bone homeostasis
by inhibiting OC formation.
The ubiquitinated protein can be degraded in proteasomes or lysosomes. CD40
or BAFF-R engagement in B cells induces rapid, proteasome-dependent TRAF3 degra-
dation [127]. However, RANKL-induced TRAF3 degradation was not blocked by the
proteasome inhibitor, MG132 [91], but was inhibited by the autophagy/lysosome inhibitor,
chloroquine (CQ) [92]. Consistent with these findings, RANKL significantly increased
co-localization of TRAF3 with LAMP2 (a lysosome marker), which was reduced by CQ [92].
Importantly, CQ also inhibited RANKL-induced OC formation from WT mouse OCPs,
but not from TRAF3−/− OCPs. Thus, RANKL degrades TRAF3 through the lysosome to
promote OC differentiation. Interestingly, TRAF3 protein levels are reduced in the bone
from aged mice and humans [94], which directly links TRAF3 deficiency to age-associated
osteoporosis. TRAF3 also inhibits OC formation indirectly by limiting NF-κB mediated
RANKL production by MPCs [94].
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In contrast to RANKL, which efficiently degrades TRAF3 to promote OC differen-
tiation, TNFα increases protein levels of TRAF3 [91], even in OCPs from TRAF6−/−
mice [93], which are osteopetrotic because TRAF6 is required for RANKL-induced OC
formation [128–130]. Interestingly, RANKL is still involved in OC formation in the absence
of TRAF6, because it degrades TNFα induction of TRAF3 [93], explaining why OCs are
still present in the bone of TRAF6−/− mice even though they are osteopetrotic [93,128].
However, the mechanism by which TNFα prevents TRAF3 degradation, or which factors
other than RANKL can degrade TRAF3 to promote OC differentiation and bone loss are
still unknown. Nevertheless, prevention of TRAF3 degradation could be a novel strategy
for the treatment of osteoporosis and RA.
5.1.3. RelB
Generally, NF-κB2 p100 associates with RelB, maintaining cytoplasmic localization,
but upon stimulation, p100 is processed to p52, resulting in the release of the p52:RelB
heterodimer, which translocates to the nucleus to activate target genes. However, TNFα in-
creases p100 mRNA expression, but does not process it to p52, resulting in the accumulation
of p100 [91]. Similarly, TNFα increases mRNA expression of RelB, but does not degrade
it [98]. This raises the question of what the role is of RelB in OC differentiation. A report has
shown that myeloid progenitor cells from RelB−/− mice have an impaired OC formation in
response to RANKL in vitro, but it is not understood why RelB−/− mice have normal OCs
on their bone in vivo [131]. In fact, RelB acts as a dual factor for OC differentiation [98].
TNFα elevates RelB protein to promote the differentiation of inflammatory macrophages
with enhanced OC forming potential [98], but elevated RelB also inhibits the terminal OC
differentiation by inhibiting NFATc1 expression [98]. TNFα stimulation therefore increases
the pool of OCPs, but alone it induces very limited OC formation. RANKL, however, can
degrade the excessively produced RelB to stimulate OC differentiation [98].
5.2. Notch Signaling Proteins
Notch is a family of evolutionarily conserved receptors that regulate cell fate. There are
four different Notch receptors, Notch 1 to 4, and five ligands, Jag1, Jag2, Delta-like 1, 3, and
4, in mammalian cells [132]. Upon ligand binding, the Notch receptor intracellular domain
(NICD) is cleaved by γ-secretase, and translocates to the nucleus, where it associates with
the recombination signal-binding protein jκ (RBPjκ), leading to transcriptional activation
or inhibition of target genes, such as Hes1 and Hey1 [132,133].
Notch signaling can directly regulate OC differentiation. Notch ligands downregulate
cFms expression on OCPs to inhibit their differentiation into OCs [99]. Thus, deletion of
Notch 1–3 in macrophages promotes their differentiation to mature Ocs in response to
a low dose of RANKL, and these macrophages undergo faster proliferation in response
to M-CSF compared to WT control cells [134]. RANKL also induces macrophages to
express Notch2, which is recruited to and interacts with RelA on NFATc1 promoter driving
its expression [135]. Notch ligands also inhibit the expression of M-CSF and RANKL
by stromal cells to negatively regulate OC differentiation in vitro [99]. Consistent with
this, specific activation of canonical Notch in osteocytes increases bone mass in mice,
associated with reduced OC formation, and bone resorption, associated with decreased
RANKL expression in these cells [100]. In contrast, osteoblast-specific loss of function
of Notch led to age-related bone loss in mice, due to increased bone resorption caused
by reduced OPG expression [101]. These reports generally suggest that Notch inhibits
OC differentiation directly from OCPs by downregulating their expression of cFms, and
indirectly in osteoblast/osteocytes by reducing RANKL and/or increasing OPG production.
TNFα mainly drives enhanced OC formation and bone resorption in pathological
conditions, raising a question as to the role of Notch signaling in TNF-induced OC differ-
entiation. Zhao and colleagues found that RBP-J, like p100, is a key negative regulator of
osteoclastogenesis that restrains TNFα-induced excessive bone resorption in inflammatory
settings [95]. In the absence of RBP-J, TNFα effectively induced osteoclastogenesis and
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bone resorption in RANK-deficient mice, and, in contrast, activation of RBP-J specific in
OCPs suppressed osteoclastogenesis and arthritic bone resorption in TNF-Tg mice [95].
Further studies indicate that RBP-J suppresses the induction of NFATc1 by attenuating c-Fos
activation, and suppressing the induction of B lymphocyte-induced maturation protein-1
(Blimp1), and thus, prevents the downregulation of transcriptional repressors, such as
IRF-8, which blocks OC differentiation [95]. This report further confirmed the concept
that TNFα-induced OC differentiation is independent of RANKL, but its ability to induce
OC formation is limited by its induction of negative regulators [91]. However, similar to
p100 knockout [91], the absence of RBP-J does not change the osteopetrotic phenotype of
RANK−/− mice, suggesting that RBP-J has minimal effects on physiological bone remod-
eling [95]. The mechanisms by which Notch signaling regulates OC differentiation are
outlined in Figure 3.
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results in the cleavage and release of Notch NICD. As a result, NICD translocates into the nucleus,
where it associates with RBPjκ and NF-κB to regulate the transcription of genes that control OC
differentiation. NICD association with RBPjκ inhibits the expression of NFATc1 by attenuating c-
Fos, and suppressing Blimp1, and promotes IRF8 expression. Notch also inhibits cFms expression,
but associates with NF-κB RelA to promote NFATc1 expression. In addition, Notch inhibits OC
differentiation, indirectly downregulating RANKL, while promoting OPG expression by MPCs
and osteocytes.
6. Regulation of OC Forming Potential through Macrophage Polarization
Macrophages are classified as classically activated (inflammatory, M1) macrophages
or alternatively activated (resident, M2) macrophages [57,136], which are linked to T helper
1 (Th1)- and Th2-type immune responses, respectively [137]. M1 macrophages mediate in-
flammatory responses to a variety of bacterial, protozoal, and viral infections, and produce
many infla matory cytokines, including TNFα, IL-12, IL-18, and IL-23, in several chronic
inflammatory and autoimmune diseases, including RA, Crohn’s disease, multiple sclerosis,
and autoim une hep titis [138,139]. M2 macrophages, in contrast, inhibit th production
of a w de variety f pro-i flamm ory mediators, through the production of cytok es, suc
as IL-10 and TGF-β, and thus, regulate wound healing [140]. T us, it is widely ac epted
that targeted depletion of M1 and boosting activities of M2 macrophages are emerging
as an attractive combined therapeutic strategy for autoimmune diseases [141–143]. How-
ever, a recent report shows that TNF-polarized macrophages (TPMs) produce insulin-like
6 peptide (INSL6) and Jagged1 to stimulate bone formation, slowing down bone loss caused
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by enhanced bone resorption in RA [144], which explains why anti-TNF therapy has a
limited effect in improving the lost bone in patients with RA [145–147].
6.1. Macrophage Generation
Monocytes and macrophages, generated from myeloid progenitor cells in bone mar-
row, are phagocytes. The circulating phagocytes in the blood are known as monocytes,
which become different types of macrophages when they enter tissues. GM-CSF and M-CSF
are the two cytokines that generate macrophages. GM-CSF drives myeloid progenitor cells,
differentiating into both granulocytes and macrophages, as well as dendritic cells (DC), and
thus, it is often employed in studies of DC development and function [148,149]. However,
GM-CSF is not critical for macrophage development, since mice lacking GM-CSF do not
have notable defects in tissue macrophages [150]. In contrast, targeted ablation of M-CSF
or its receptor, c-Fms, causes severe depletion of macrophages in many tissues associated
with the failure of OC formation and osteopetrosis [57], indicating that M-CSF does play a
major role in the generation of macrophages. Importantly, M-CSF generated macrophages
can be polarized to the cells with either a stronger M2 anti-inflammatory [102,151–153] or
M1 inflammatory cytokine profile [102], and thus, they are called M0 macrophages [153].
Macrophage polarization can have a profound effect on their OC forming potential.
6.2. Polarized M1 Macrophages with Altered OC Forming Potential
IFN-γ and lipopolysaccharide (LPS) are traditionally considered as factors which po-
larize M1s [102], with GM-CSF and TNFα being the latest additions to M1 category of
stimuli [98,102,152]. The hallmarks of M1 activation are iNOS expression and high levels of
IL-12 with low levels of IL-10 production [102]. A recent report shows that TNF-polarized
macrophages do not produce iNOS, although they express the major M1 surface mark-
ers [144]. RANKL can stimulate the expression of iNOS, which acts as an autocrine negative
feedback mechanism to restrain RANKL-mediated osteoclastogenesis [154]. Similarly, IL-12,
like IL-18, was shown to potently inhibit OC formation partially via Fas- and FasL-mediated
apoptosis [106,107].
M-CSF-induced macrophages are polarized to M1 via stimulating transcription factors
signal transducer and activator of transcription 1 (STAT1) and interferon-regulatory factor
(IRF) family members, including IRF1, IRF5, and IRF8 [155,156], which are implicated in
the differentiation of Th1 cells by regulating transcription of interferon. These transcrip-
tion factors also inhibit RANKL-induced OC formation. STAT1 deficiency dramatically
prevented IFN-γ, IFN-β, and LPS inhibition of RANKL-induced OC formation [103,108],
suggesting that STAT1 mediates IFN-γ, IFN-β, and LPS inhibition of RANKL-induced
OC differentiation.
Zhao and colleagues reported that OCPs from IRF8−/− mice underwent increased
osteoclastogenesis in response to both RANKL and TNFα [96]. Consistent with this,
mice deficient in IRF8 showed severe osteoporosis due to increased OC formation, and
enhanced bone destruction following LPS administration [96]. These findings suggest that
the expression of IRF8, like p100 and RBP-j, in OCPs limits TNF-induced OC differentiation.
In contrast, RANKL can downregulate IRF8 to initiate OC differentiation [96]. Consistent
with these, mutation of the IRF8 gene promotes OC formation to increase the susceptibility
to tooth root resorption in humans [97].
Both IFN-γ and GM-CSF strongly inhibit OC differentiation [103,157]. M1 macrophages
polarized by LPS in cooperation with IFN-γ do not form TRAP+ OCs, but fuse to form
multinucleated giant cells (MGCs) [158,159]. M1 macrophages polarized by LPS alone also
fail to form OCs in response to RANKL [104]. However, LPS stimulates OC formation
from RANKL-primed pre-OCs indirectly by stimulating TNFα and IL-1β production, al-
though LPS directly inhibits RANKL-induced OC formation [105]. TNFα alone weakly
induces OC differentiation that is independent of RANKL signaling [72]. Different from
M1 macrophages polarized by IFN-γ, GM-CSF, or LPS, TNF-polarized M1 are versatile and
have enhanced OC forming potential in response to RANKL, and TNFα does not inhibit
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RANKL induction of OC differentiation in its polarized cells [98], although TNFα inhibits
RANKL-induced OC formation from M-CSF-induced macrophages [91].
6.3. Polarized M2 Macrophages with Reduced OC Forming Potential
M-CSF generated macrophages mainly have the M2 phenotype [102]. Like Th1 cy-
tokine IFN-γ, Th2 cytokine IFN-β also inhibits RANKL-induced OC formation [160]. Th2-
linked M2 macrophages are not a uniform population, and are often subdivided into M2a,
M2b, and M2c categories [102]. The common denominator of all three M2 subpopula-
tions in mice are high IL-10 production, and low production of IL-12, accompanied by the
production of enzyme arginase-1, which depletes L-arginine, thereby suppressing T cell
responses and depriving iNOS of its substrate [102,161]. M2a macrophages are induced
by IL-4 and IL-13, and produce TGF-β and IL-1Ra alongside IL-10. M2b macrophages are
induced by LPS and immune complexes, and produce IL-1, IL-6, and TNFα, in addition to
IL-10. M2c macrophages are induced by IL-10 and TGF-β, and produce large amounts of
IL-10 and TGF-β such that they are often referred to as anti-inflammatory macrophages,
and are involved in tissue repair and remodeling [102,161]. However, TGFβ1 enhances
TNFα-induced OC formation, which is independent of TRAF6 [87,93]. Particularly, ele-
vated active TGFβ1 with aging induces TRAF3 lysosomal degradation in mesenchymal
progenitor cells to inhibit bone formation directly through GSK-3β mediated β-catenin
degradation, and to promote OC formation indirectly through NF-κB mediated RANKL
production [94], forming the basis of age-related osteoporosis.
IL-4, produced by Th2 lymphocytes, is the traditional trigger cytokine for M2
macrophages [102,161]. It directly prevents OC differentiation from OCPs and actin ring
formation through the induction of STAT6 [109,110], and suppression of RANK, NF-κB,
MAPK, c-Fos, and NFATc1 expression, as well as calcium signaling [109,110,162]. In addi-
tion, IL-4 indirectly suppresses osteoclastogenesis by inhibiting RANKL, but enhancing
OPG expression by stromal cells [109,110]. Mice over-expressing IL-4 do, however, develop
an osteoporotic phenotype in vivo due to inhibition of bone formation [163]. Thus, the net
effect of IL-4 on bone turnover in vivo represents an integrated outcome of its influence on
various cell populations.
IL-13 and IL-4 are closely related cytokines. Like IL-4, IL-13 is also produced by Th2
lymphocytes, and induces M2 macrophage polarization [97,111]. Similar to IL-4, IL-13
inhibits OC differentiation directly by inducing STAT6 phosphorylation in the myeloid
cells, and indirectly by stimulating OPG while suppressing RANKL production by stromal
cells [109,110].
IL-10 is highly expressed by all three subtypes of M2 macrophages, and it serves to in-
hibit inflammation by suppressing TNFα and IL-1β production and function [97,111]. IL-10
is a key negative regulator of bone resorption [111,112,164–166], and inhibits OC formation
directly by suppressing RANKL-induced NFATc1, c-Fos, and c-Jun expression [111,112],
and indirectly by reducing RANKL while increasing OPG expression by stromal cells [164].
IL-1β and TGFβ can be produced by activated M2 macrophages [97,111] and also by
many other cell types, including platelets [167] and T cells [168]. TGFβ, in particular, is
a bone matrix protein, which is released through bone resorption, and activated by the
acidic environment generated by activated OCs [169]. Both IL-1β and TGFβ cooperate with
TNFα to induce OC differentiation, and enhance bone resorption independent of RANKL
signaling [87,88], and are discussed separately below.
6.4. OC Forming Potential from Unclassified Polarized Macrophages
There are multiple macrophage phenotypes that cannot be readily classified into
any of the M1 or M2 groups, for example, tumor-associated macrophages (TAM) and
IL-17- induced atypical M2-like macrophage subpopulations [170]. It was reported that
TAMs from human breast cancer samples formed OCs in both RANKL-dependent and
-independent mechanisms [171]. Although TNFα can directly induce OC formation from
TAMs in Ewing’s sarcoma in the presence of M-CSF [172], it is unknown if TNFα- induced
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OCs from TAMs have any difference with those from normal macrophages, because TNFα
induces RANKL-independent OC formation from normal macrophages [72,86–88,91,93]. It
is also unknown if IL-17 polarized macrophages can alter their potential to form OCs.
7. Cytokines That Enhance TNFα Induction of OC Differentiation
7.1. IL-1β
IL-1β has long been known to stimulate bone resorption [173]. It is produced by
a variety of cell types at sites of inflammation in and around bones, including mono-
cytes/macrophages, and mature OC themselves [174,175]. Like TNFα, it promotes RANKL
expression by marrow osteoblastic stromal cells to induce osteoclastogenesis indirectly [176].
Wei and colleagues also found that IL-1β mediates TNF-induced osteoclastogenesis by
enhancing stromal cell expression of RANKL [177]. These findings generally suggest that,
unlike TNFα, IL-1β alone does not directly induce OC formation from OCPs [86], but
synergizes with TNFα to promote OC formation [88]. However, IL-1β can directly induce
OC formation from TNFα pre-activated OCPs expressing c-Fos, and this process is inde-
pendent of NF-κB p50 and p52 [88]. Particularly, the pre-activated OCPs interact with the
SIBLING (small integrin-binding ligand, N-linked glycoprotein) family of bone matrix
proteins, such as dentin sialoprotein (DSP) and osteopontin (OPN) [178,179], to produce
IL-1β in an autocrine mechanism, driving themselves’ to differentiate into mature OCs to
resorb bone [88]. It is unknown if IL-1β enhances TNFα-induced OC formation through
reducing any inhibitory factor proteins, including TRAF3, p100, RBP-J, and IRF8.
7.2. TGFβ1
TGFβ1 was reported to repress RANKL while increasing OPG expression by os-
teoblasts to indirectly inhibit OC formation [180,181]. Since TGFβ is released from the bone
matrix due to bone resorption, and is activated in the acid environment generated by the
activated OCs, its reduction of RANKL and increase of OPG production thus acts as feed-
back signal to limit bone resorption [182]. In contrast, a low dose of TGFβ1 stimulates OC
differentiation by increasing RANKL while reducing OPG expression by osteoblasts [180].
TGFβ1 was also reported to directly promote RANKL-induced OC formation [183,184],
or even induce OC formation in the absence of RANKL [185]. It mediates the interaction
between smad3 and TRAF6 in OCPs to promote RANKL-induced OC formation [186]. In
addition, combined stimulation of TGFβ1 and TNFα induces WT mouse spleen cells to
form a considerable number of TRAP+ OCs in the presence of M-CSF, and also induces
RAW264.7 cells to form mature OCs [183]. As discussed above, TNFα alone induces OC
differentiation from RANKL−/− and RANK −/− spleen cells [91]. Interestingly, TGFβ1
can enhance TNFα-induced OC formation from TRAF6−/− spleen cells [93]. However,
TRAF6−/− mice are still osteopetrotic [87], suggesting that TGFβ/TNFα-induced OCs
do not play major role in normal conditions. Nevertheless, TGFβ1 is one of the strong
candidate factors that enhance TNFα-mediated OC formation and bone destruction in
pathological conditions [72,91]. It is likely that TGFβ1 enhancement of TNFα-mediated OC
formation is not through degrading TRAF3 [93], but it is unknown if TGFβ1 reduces any
other TNFα- induced inhibitory factors, such as p100, RBP-J, and IRF8, in this process.
8. Limitations of Anti-TNF Therapy to Improve Osteoporosis in RA
The risk of bone loss and fracture is increased in individuals with RA and other
autoimmune diseases [187] because OCs, mediated by inflammatory factors, such as
TNFα and IL-1β, induce not only erosion of cartilage and bone locally in affected joints,
but also degradation of bone systemically [188]. Anti-TNF therapies have significantly
improved the outcomes for RA patients in the past two decades, although they have
not provided a complete cure or lasting remission [189,190]. Some reports show that
TNF inhibitors increase BMD, associated with decreased markers of bone resorption and
increased markers of bone formation [191,192]; however, other reports show that TNF
inhibitors do not increase new bone formation [193]. Long-term treatment with TNF
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inhibitors even increases the rate of fracture, although BMD is increased in patients with
ankylosing spondylitis [145]. Lee et al. found that anti-TNF therapy does not increase
lumbar and femoral neck BMD in RA patients also receiving a bisphosphonate [146].
Lumbar and femoral neck BMD are even reduced after short-term anti-TNF therapy in
patients with RA [147].
Many factors, including disease severity or activity and glucocorticoid treatment,
which accelerates bone loss, could influence the effect of anti-TNF agents on bone mass in
RA patients [146,187,194,195], and explain the discrepancies in these reported outcomes. In
6-week-old TNF-Tg mice with early-stage erosive arthritis, 4 weeks of TNF antibody treat-
ment completely blocked the development of erosive arthritis, but only slightly increased
vertebral bone mass, associated with a reduction in parameters of both bone resorption and
formation [144]. Similarly, TNF antibody slightly increased trabecular bone mass in tibiae
of 8-month-old TNF-Tg mice with advanced erosive arthritis [144]. Interestingly, TNFα
increased osteoblast differentiation from bone marrow stromal cells containing a large num-
ber of macrophages, but not from pure mesenchymal progenitor cells (MPCs) [144]. Further
analysis indicated that TNFα-polarized macrophages (TPMs) produced several anabolic
factors, including Jagged1 and insulin-like 6 (INSL6). Consistent with this, anti-TNF Ab re-
duced INSL6 expression by macrophages in vitro, and in TNF-Tg mice in vivo. Importantly,
inhibition of either Jagged1 or INSL6 blocked TNFα-induced osteoblast differentiation from
bone marrow stromal cells [144]. This is consistent with the known function of Jagged1
that stimulates osteoblast differentiation, and maintains the osteoblastic osteoprogenitor
pool [196,197]. Similarly, INSL6 functions to expand MPCs. Of note, TPM stimulation of
osteoblast differentiation is unique, as this did not occur with resident and inflammatory
macrophages polarized by IL-4 and interferon-λ [144]. These findings suggest that TPMs
produce INSL6 and Jagged 1 to stimulate bone formation, and that anti-TNF Ab blocks not
only enhanced bone resorption, but also the anabolic effect of TPMs on bone, limiting its
ability to increase bone mass in this model of RA.
9. Prospective
The RANKL/OPG system is critical to control OC formation [80], whereas TNFα
appears to contribute pathological bone loss and joint destruction [198]. The potential of
TNFα induction of OC differentiation is weak [72,91], since it also increases many inhibitory
proteins, including TRAF3 [91,92], p100 [91], IRF8 [96], and RBP-j [95]. However, TNFα
induction of OC differentiation is versatile. IL-1 or TGFβ enhances TNFα induction of
OC formation [88,183], which is independent of the RANKL/RANK/TRAF6 axis or NF-
κB [87,88]. Anti-TNF regents have significantly improved the treatment of RA; however,
about 50% of RA patients do not respond to anti-TNF reagents [199,200]. It is not known
if these patients have genetic variants of the inhibitory proteins, such as TRAF3, p100,
and RBP-J, resulting in the loss of function of these proteins, thus limiting the role of
anti-TNF reagents. In most cases, RANKL degrades these inhibitory proteins to induce
constitutive OC differentiation [87,91,92,95], but it is not known if any other factor can
decrease TNFα induction of these inhibitory proteins to enhance TNFα induction of OC
formation and bone destruction. Nevertheless, elevation or stabilization of these inhibitory
proteins, including TRAF3, p100, IRF8, and RBP-J, would be a novel strategy to treat
a variety of bone diseases with bone loss, including osteoporosis and RA. It should be
noticed that anti-TNF regents do not improve the lost bone in patients with rheumatoid
diseases [145–147], because anti-TNF therapy not only blocks the enhanced bone resorption,
but also the anabolic effects of TNF-polarized macrophages [144]. Therefore, targeting
TNFα signaling to develop novel approaches in treating bone diseases with increased
resorption should focus on its downstream molecules that do not block the anabolic effect
from its polarized macrophages.
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